Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Pharmacokinetics with High Fat Diet in Advanced Cancer
NCT02825563Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anlotinib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), soft tissue sarcoma (STS) and 1 more (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration up to 14 Days and Area under the plasma concentration versus time curve up to 14 Days. Started Jun 2016; status: completed.
02
Drugs
anlotinib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT02825563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02825563.